Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Immunoglobulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
jRCT1061220010Recruiting
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of immune globulin in idiopathic pulmonary fibrosis (IPF). Primary endpoint: survival proportion on day 90 (confirmed cases by central review). Started Aug 2022; status: recruiting.
02
Drugs
immune globulin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT1061220010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061220010.